www.eigerbio.com Open in urlscan Pro
2606:4700:20::681a:7c6  Public Scan

Form analysis
2 forms found in the DOM

GET https://www.eigerbio.com/

<form role="search" method="get" id="searchform" class="searchform" action="https://www.eigerbio.com/">
  <input type="text" id="s" name="s" value="" placeholder="Search">
  <button type="submit" id="searchsubmit"><i class="fas fa-search" aria-hidden="true"></i></button>
</form>

GET https://www.eigerbio.com/

<form role="search" method="get" id="searchform" class="searchform" action="https://www.eigerbio.com/">
  <input type="text" id="s" name="s" value="" placeholder="Search">
  <button type="submit" id="searchsubmit"><i class="fas fa-search" aria-hidden="true"></i></button>
</form>

Text Content

 * About
   * Team
 * Investors
   * Stock Information
   * Press Releases
   * Events & Presentations
   * SEC Filings
   * Corporate Governance
   * Shareholder Services
   * Analyst Coverage
 * Pipeline
   * Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
   * Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
   * Avexitide for Post-Bariatric Hypoglycemia (PBH)
   * Avexitide for Congenital Hyperinsulinism (HI)
 * ZOKINVY®
 * Resources
   * Zokinvy® European SmPC
   * Expanded Access Policy
   * Contact Us
   * Privacy Policy
   * Social Media Guidelines
   * Terms and Conditions
 * Careers

 * About
   * Team
 * Investors
   * Stock Information
   * Press Releases
   * Events & Presentations
   * SEC Filings
   * Corporate Governance
   * Shareholder Services
   * Analyst Coverage
 * Pipeline
   * Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
   * Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
   * Avexitide for Post-Bariatric Hypoglycemia (PBH)
   * Avexitide for Congenital Hyperinsulinism (HI)
 * ZOKINVY®
 * Resources
   * Zokinvy® European SmPC
   * Expanded Access Policy
   * Contact Us
   * Privacy Policy
   * Social Media Guidelines
   * Terms and Conditions
 * Careers


INNOVATIVE THERAPIES FOR
HEPATITIS DELTA VIRUS
AND OTHER SERIOUS DISEASES

ABOUT US





DEVELOPING AND COMMERCIALIZING FIRST-IN-CLASS, WELL-CHARACTERIZED DRUGS FOR
LIFE-THREATENING, RARE AND SERIOUS DISEASES WITH HIGH UNMET MEDICAL NEEDS AND NO
APPROVED THERAPIES.






IN THE NEWS

October 11, 2022

EIGER BIOPHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT THIRD ANNUAL
HEPATITIS B VIRUS (HBV) VIRTUAL CONFERENCE

PALO ALTO, Calif. , Oct. 11, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the
development of innovative therapies for hepatitis delta virus (HDV) and other
serious diseases, today announced that David Cory , President and

October 5, 2022

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE
AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

PALO ALTO, Calif. , Oct. 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the
development of innovative therapies for hepatitis delta virus (HDV) and other
serious diseases, today announced that, following feedback from

September 22, 2022

EIGER BIOPHARMACEUTICALS TO PRESENT AT THE 2022 LADENBURG THALMANN HEALTHCARE
CONFERENCE

PALO ALTO, Calif. , Sept. 22, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals,
Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the
development of innovative therapies for hepatitis delta virus (HDV) and other
serious diseases, today announced that David Cory , President

SEE ALL
About Eiger Biopharmaceuticals

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2022 Eiger BioPharmaceuticals. All Rights Reserved.



Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2022 Eiger BioPharmaceuticals. All Rights Reserved.


MODAL TEMPLATE